Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Physiology of continuous-flow pumps.

AACN advanced critical care·2012

Same author

Managing heart failure: what you need to know.

Nursing·2005

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Extreme heart makeover: understanding mechanical circulatory support.

Dawn M Christensen¹

¹Penn State's Milton S. Hershey Medical Center, Hershey, PA, USA.

|April 24, 2008

Summary

Ventricular assist devices and total artificial hearts are advanced treatments for heart failure. These devices significantly impact patient care and quality of life.

Area of Science:

Cardiology
Medical Devices
Surgical Technology

Background:

End-stage heart failure necessitates advanced therapeutic options.
Ventricular assist devices (VADs) and total artificial hearts (TAHs) offer life-saving interventions.
Understanding their impact on patient care is crucial for clinical practice.

Purpose of the Study:

To provide an overview of ventricular assist devices (VADs) and total artificial hearts (TAHs).
To explore the multifaceted effects of VADs and TAHs on patient care.
To highlight key considerations for managing patients with these advanced cardiac support systems.

Main Methods:

Review of current literature on VADs and TAHs.
Analysis of clinical outcomes and patient management strategies.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Related Experiment Videos

Last Updated: Jul 5, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Synthesis of data regarding device implantation and long-term support.

Main Results:

VADs and TAHs have demonstrated improved survival rates for eligible heart failure patients.
Significant improvements in functional capacity and quality of life are observed.
Management requires a multidisciplinary approach, addressing physiological and psychological aspects.

Conclusions:

Ventricular assist devices and total artificial hearts represent critical advancements in treating advanced heart failure.
These devices profoundly influence patient care, necessitating specialized medical and nursing support.
Continued research and technological innovation are vital for optimizing outcomes and expanding patient eligibility.